{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:12:51Z","timestamp":1792257171225,"version":"4.4.0"},"reference-count":230,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Echinocandins are the newest addition of the last decade to the antifungal armamentarium, which, owing to their unique mechanism of action, selectively target the fungal cells without affecting mammalian cells. Since the time of their introduction, they have come to occupy an important niche in the antifungal pharmacotherapy, due to their efficacy, safety, tolerability and favourable pharmacokinetic profiles. This review deals with the varying facets of echinocandins such as their chemistry, in-vitro and in-vivo evaluations, clinical utility and indications, pharmacokinetic and pharmacodynamic profiles, and pharmacoeconomic considerations.<\/jats:p>\n <\/jats:sec>\n \n Key findings<\/jats:title>\n Clinical studies have demonstrated that the echinocandins \u2013 caspofungin, micafungin and anidulafungin \u2013 are equivalent, if not superior, to the mainstay antifungal therapies involving amphotericin B and fluconazole. Moreover, echinocandin regimen has been shown to be more cost-effective and economical. Hence, the echinocandins have found favour in the management of invasive systemic fungal infections.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The subtle differences in echinocandins with respect to their pharmacology, clinical therapy and the mechanisms of resistance are emerging at a rapid pace from the current pool of research which could potentially aid in extending their utility in the fungal infections of the eye, heart and nervous system.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jphp.12780","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T08:54:58Z","timestamp":1501059298000},"page":"1635-1660","source":"Crossref","is-referenced-by-count":128,"title":["Echinocandins in antifungal pharmacotherapy"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-6452","authenticated-orcid":false,"given":"Akash","family":"Patil","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi , Oxford, MS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi , Oxford, MS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"2024103013040556000_jphp12780-cit-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae) \u2013 a case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat Prod Rep"},{"key":"2024103013040556000_jphp12780-cit-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections","volume":"1","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"2024103013040556000_jphp12780-cit-0003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/jm00079a027","article-title":"Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic Candidiasis and Pneumocystis carinii pneumonia (PCP)","volume":"35","author":"Balkovec","year":"1992","journal-title":"J Med Chem"},{"key":"2024103013040556000_jphp12780-cit-0004","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1128\/AAC.38.7.1480","article-title":"Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase","volume":"7","author":"Kurtz","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0005","first-page":"231","article-title":"Comparative antifungal activity of cilofungin (LY121019) against Candida species, including evaluation of susceptibility testing method","volume":"5","author":"Chagla","year":"1992","journal-title":"Can J Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0006","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0960-894X(99)00290-5","article-title":"The synthesis of water soluble prodrugs analogs of echinocandin B","volume":"9","author":"Rodriguez","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103013040556000_jphp12780-cit-0007","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/jm00017a012","article-title":"Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB","volume":"38","author":"Debono","year":"1995","journal-title":"J Med Chem"},{"key":"2024103013040556000_jphp12780-cit-0008","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7164\/antibiotics.42.174","article-title":"L-671,329, a new antifungal agent, III. In vitro activity, toxicity and efficacy in comparison to aculeacin","volume":"2","author":"Fromtling","year":"1989","journal-title":"J Antibiot"},{"key":"2024103013040556000_jphp12780-cit-0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ja.2008.3","article-title":"Micafungin: a sulfated echinocandin","volume":"1","author":"Hashimoto","year":"2009","journal-title":"J Antibiot"},{"key":"2024103013040556000_jphp12780-cit-0010","first-page":"943","article-title":"Caspofungin: a major breakthrough in treatment of systemic fungal infections","volume":"54","author":"Agarwal","year":"2006","journal-title":"J Assoc Physicians India"},{"key":"2024103013040556000_jphp12780-cit-0011","first-page":"198","article-title":"Update on azole antifungals","volume":"2","author":"Dimitrios","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"2024103013040556000_jphp12780-cit-0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0013","first-page":"248","article-title":"Topical delivery of lipid based amphotericin B gel in the treatment of fungal infection: a clinical efficacy, safety and tolerability study in patients","volume":"5","author":"Sheikh","year":"2014","journal-title":"J Clin Exp Dermatol Res"},{"key":"2024103013040556000_jphp12780-cit-0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.01078-10","article-title":"Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections","volume":"1","author":"Gorski","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0015","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"6","author":"Wang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0016","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4236\/pp.2013.43052","article-title":"Cardiac toxicity of azole antifungals","volume":"4","author":"Cleary","year":"2013","journal-title":"Pharmacol Pharm"},{"key":"2024103013040556000_jphp12780-cit-0017","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"6","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0018","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4254\/wjh.v7.i14.1828","article-title":"Voriconazole and the liver","volume":"14","author":"Mih\u0103il\u0103","year":"2015","journal-title":"World J Hepatol"},{"key":"2024103013040556000_jphp12780-cit-0019","volume-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Posaconazole \u2013 Drug Record"},{"key":"2024103013040556000_jphp12780-cit-0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0021","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"2024103013040556000_jphp12780-cit-0022","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.43.3.702","article-title":"Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides","volume":"43","author":"Helmerhorst","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0014-5793(96)01360-9","article-title":"Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation","volume":"400","author":"Kelly","year":"1997","journal-title":"FEBS Lett"},{"key":"2024103013040556000_jphp12780-cit-0024","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkf045","article-title":"Echinocandins: a new class of antifungal","volume":"6","author":"Denning","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"1","author":"Eschenauer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2024103013040556000_jphp12780-cit-0026","volume-title":"Mycamine - Micafungin Sodium Injection (Drug Approval Package)","year":"2005"},{"key":"2024103013040556000_jphp12780-cit-0027","volume-title":"Eraxis - Anidulafungin injection (Drug Approval Package)","year":"2006"},{"key":"2024103013040556000_jphp12780-cit-0028","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0029","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0030","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: a new echinocandin","volume":"8","author":"Chandrasekar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0031","first-page":"241","article-title":"Anidulafungin: an evidence-based review of its use in invasive fungal infections","volume":"2","author":"Davis","year":"2007","journal-title":"Core Evid"},{"key":"2024103013040556000_jphp12780-cit-0032","first-page":"2459","article-title":"[Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components]","volume":"8","author":"Nyfeler","year":"1974","journal-title":"Helv Chim Acta"},{"key":"2024103013040556000_jphp12780-cit-0033","first-page":"152","article-title":"Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B","volume":"1","author":"Debono","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"2024103013040556000_jphp12780-cit-0034","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/24.3.325","article-title":"In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B","volume":"3","author":"Meunier","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0035","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.7164\/antibiotics.45.1886","article-title":"Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species","volume":"12","author":"Schmatz","year":"1992","journal-title":"J Antibiot"},{"key":"2024103013040556000_jphp12780-cit-0036","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2016","journal-title":"N Engl J Med"},{"key":"2024103013040556000_jphp12780-cit-0037","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1021\/jo062008i","article-title":"Synthesis of the antifungal \u03b2-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0","volume":"7","author":"Leonard","year":"2007","journal-title":"J Org Chem"},{"key":"2024103013040556000_jphp12780-cit-0038","first-page":"445","article-title":"Major antifungal drugs","volume-title":"Comprehensive Medicinal Chemistry II: Vol. 7","author":"Bell","year":"2006"},{"key":"2024103013040556000_jphp12780-cit-0039","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7164\/antibiotics.42.382","article-title":"Deacylation of echinocandin B by Actinoplanes utahensis","volume":"3","author":"Boeck","year":"1989","journal-title":"J Antibiot"},{"key":"2024103013040556000_jphp12780-cit-0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/op800055h","article-title":"Commercialization and late-stage development of a semisynthetic antifungal API: anidulafungin\/d-fructose (Eraxis)","volume":"3","author":"Norris","year":"2008","journal-title":"Org Process Res Dev"},{"key":"2024103013040556000_jphp12780-cit-0041","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.tet.2012.02.015","article-title":"Total synthesis and structure\u2013activity relationships of caspofungin-like macrocyclic antifungal lipopeptides","volume":"14","author":"Yao","year":"2012","journal-title":"Tetrahedron"},{"key":"2024103013040556000_jphp12780-cit-0042","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/46.3.485","article-title":"In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide","volume":"3","author":"Mikamo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0043","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1039\/C4NP00046C","article-title":"New insights into the echinocandins and other fungal non-ribosomal peptides and peptaibiotics","volume":"10","author":"Bills","year":"2014","journal-title":"Nat Prod Rep"},{"key":"2024103013040556000_jphp12780-cit-0044","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/jm00093a018","article-title":"Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach","volume":"15","author":"Zambias","year":"1992","journal-title":"J Med Chem"},{"key":"2024103013040556000_jphp12780-cit-0045","first-page":"215","article-title":"Anidulafungin: a novel echinocandin","volume":"2","author":"Vazquez","year":"2006","journal-title":"Oxford"},{"key":"2024103013040556000_jphp12780-cit-0046","first-page":"159","article-title":"1,3-beta-glucan synthase: a useful target for antifungal drugs","volume":"2","author":"Liu","year":"2002","journal-title":"Curr Drug Targets Infect Disord"},{"key":"2024103013040556000_jphp12780-cit-0047","first-page":"1445","article-title":"Caspofungin","volume":"11","author":"Deresinski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0048","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.fgb.2015.12.004","article-title":"\u03b2-glucan: crucial component of the fungal cell wall and elusive MAMP in plants","volume":"90","author":"Fesel","year":"2016","journal-title":"Fungal Genet Biol"},{"key":"2024103013040556000_jphp12780-cit-0049","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/jop.2016.0186","article-title":"Echinocandins in ocular therapeutics","volume":"33","author":"Patil","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"2024103013040556000_jphp12780-cit-0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/00362178185380161","article-title":"Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study","volume":"2","author":"Cassone","year":"1981","journal-title":"Sabouraudia"},{"key":"2024103013040556000_jphp12780-cit-0051","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/JCM.40.6.2228-2230.2002","article-title":"In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance","volume":"40","author":"Bachmann","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0052","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1128\/AAC.48.7.2730-2732.2004","article-title":"Micafungin enhances neutrophil fungicidal functions against candida pseudohyphae","volume":"48","author":"Gil-Lamaignere","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0053","first-page":"78","article-title":"[The fungal cell wall and the mechanism of action of anidulafungin]","volume":"2","author":"Ponton","year":"2008","journal-title":"Revista iberoamericana de micologia"},{"key":"2024103013040556000_jphp12780-cit-0054","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1130-1406(08)70025-1","article-title":"[In vitro antifungal activity of anidulafungin]","volume":"2","author":"Quindos","year":"2008","journal-title":"Revista iberoamericana de micologia"},{"key":"2024103013040556000_jphp12780-cit-0056","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0924-8579(02)00240-6","article-title":"Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods","volume":"6","author":"Laverdiere","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"2024103013040556000_jphp12780-cit-0057","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1128\/AAC.46.11.3591-3596.2002","article-title":"In vitro activity of caspofungin against Candida albicans biofilms","volume":"11","author":"Bachmann","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0058","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1128\/JCM.41.12.5729-5731.2003","article-title":"Caspofungin activity against clinical isolates of fluconazole-resistant Candida","volume":"12","author":"Pfaller","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0059","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1469-0691.2008.02660.x","article-title":"Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit","volume":"3","author":"Ghannoum","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2024103013040556000_jphp12780-cit-0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jac\/dki269","article-title":"Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms","volume":"56","author":"Cocuaud","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0061","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2009","journal-title":"N Engl J Med"},{"key":"2024103013040556000_jphp12780-cit-0062","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1590\/S0074-02762012000300022","article-title":"The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates","volume":"3","author":"Mario","year":"2012","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2024103013040556000_jphp12780-cit-0063","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11046-011-9459-x","article-title":"Broth microdilution and time-kill testing of caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei","volume":"1","author":"Oz","year":"2012","journal-title":"Mycopathologia"},{"key":"2024103013040556000_jphp12780-cit-0064","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.44.3.760-763.2006","article-title":"In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance","volume":"3","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0065","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.49.9.3616-3623.2005","article-title":"Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome","volume":"49","author":"Kartsonis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0066","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JCM.00566-08","article-title":"Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints","volume":"8","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0067","doi-asserted-by":"crossref","first-page":"236903","DOI":"10.1155\/2013\/236903","article-title":"In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method","volume":"2013","author":"Fahriye","year":"2013","journal-title":"ScientificWorldJournal"},{"key":"2024103013040556000_jphp12780-cit-0068","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00802-08","article-title":"Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies","volume":"11","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0069","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3201\/eid1801.110556","article-title":"Candida spp. with acquired echinocandin resistance, France, 2004\u20132010","volume":"18","author":"Dannaoui","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0070","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1128\/JCM.00053-08","article-title":"Detection of caspofungin resistance in Candida spp. by Etest","volume":"46","author":"Desnos-Ollivier","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0071","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.00443-09","article-title":"Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-\u03b2-d-glucan synthase: implication for the existing susceptibility breakpoint","volume":"9","author":"Garcia-Effron","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0072","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/AAC.00148-06","article-title":"Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy","volume":"50","author":"Hakki","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0073","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/JCM.44.2.324-326.2006","article-title":"Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp","volume":"2","author":"Messer","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0074","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/AAC.46.12.3846-3853.2002","article-title":"In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies","volume":"12","author":"Ernst","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/cipms-2015-0033","article-title":"The activity of micafungin against clinical isolates of non-albicans Candida spp","volume":"1","author":"Biernasiuk","year":"2015","journal-title":"Curr Issue Pharm Med Sci"},{"key":"2024103013040556000_jphp12780-cit-0076","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13693780802262123","article-title":"Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan","volume":"47","author":"Ikeda","year":"2009","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0077","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0078","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/AAC.01569-10","article-title":"In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species","volume":"55","author":"Fiori","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0079","first-page":"588","article-title":"Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms","volume":"3","author":"Katragkou","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0080","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1086\/652783","article-title":"Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents","volume":"12","author":"Katragkou","year":"2010","journal-title":"J Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0081","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","article-title":"Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis","volume":"2","author":"Moudgal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0082","first-page":"1724","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"12","author":"Alexander","year":"2013","journal-title":"Oxford"},{"key":"2024103013040556000_jphp12780-cit-0083","first-page":"24","article-title":"Two echinocandin-resistant Candida glabrata FKS mutants from South Africa","volume":"11","author":"Naicker","year":"2016","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0084","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12866-015-0442-4","article-title":"Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods","volume":"1","author":"Montagna","year":"2015","journal-title":"BMC Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0085","first-page":"8","article-title":"Antifungal susceptibility of Candida albicans isolated from the oral cavities of patients with HIV infection and cancer","volume":"1","author":"Owotade","year":"2016","journal-title":"S Afr Dent J"},{"key":"2024103013040556000_jphp12780-cit-0086","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1128\/AAC.45.1.327-330.2001","article-title":"In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates","volume":"45","author":"Arikan","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0087","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1128\/AAC.49.12.5133-5135.2005","article-title":"Efficacy of caspofungin against Aspergillus terreus","volume":"12","author":"Barchiesi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0088","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/AAC.47.4.1416-1418.2003","article-title":"In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points","volume":"4","author":"Shalit","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0089","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"10","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0090","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1128\/AAC.02026-15","article-title":"Albumin enhances caspofungin activity against Aspergillus species by facilitating drug delivery to germinating hyphae","volume":"3","author":"Ioannou","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0091","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.diagmicrobio.2007.10.015","article-title":"Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro","volume":"4","author":"Natesan","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0092","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.01543-08","article-title":"Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds","volume":"5","author":"Cuenca-Estrella","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0093","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/48.5.713","article-title":"Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis","volume":"48","author":"M\u00fcller","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0094","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijantimicag.2011.06.008","article-title":"Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo","volume":"4","author":"Calvo","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2024103013040556000_jphp12780-cit-0095","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.42.10.2726","article-title":"In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp","volume":"10","author":"Oakley","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0096","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/mmy\/myv027","article-title":"Experimental efficacy of anidulafungin against Aspergillus terreus species complex","volume":"6","author":"Sanchis","year":"2015","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0097","first-page":"44","article-title":"Novel, broad-specrum antimycotic agents: the role of echinocandins today","volume":"3","author":"Manfredi","year":"2010","journal-title":"AVFT"},{"key":"2024103013040556000_jphp12780-cit-0098","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/11315560-000000000-00000","article-title":"Anidulafungin, a new echinocandin","volume":"69","author":"Morace","year":"2009","journal-title":"Drugs"},{"key":"2024103013040556000_jphp12780-cit-0099","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/AAC.00190-08","article-title":"Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins","volume":"10","author":"Arendrup","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0100","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1080\/13693780400029023","article-title":"Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin","volume":"43","author":"Gardiner","year":"2005","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0101","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1128\/AAC.48.5.1912-1915.2004","article-title":"In vitro activity of anidulafungin against selected clinically important mold isolates","volume":"48","author":"Odabasi","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0102","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.41.8.1835","article-title":"In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds","volume":"8","author":"Del Poeta","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0103","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0104","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.47.4.1376-1381.2003","article-title":"In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms","volume":"47","author":"Nakai","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0105","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1128\/AAC.46.11.3394-3400.2002","article-title":"Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin","volume":"11","author":"Van Duin","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0106","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.00105-07","article-title":"In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera","volume":"5","author":"Wiederhold","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0107","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1099\/jmm.0.000116","article-title":"Dose escalation studies with caspofungin against Candida glabrata","volume":"64","author":"Dom\u00e1n","year":"2015","journal-title":"J Med Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0108","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jis594","article-title":"The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms","volume":"11","author":"Bink","year":"2012","journal-title":"J Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0109","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dks180","article-title":"In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis","volume":"9","author":"Spreghini","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0110","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"6","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0111","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkf247","article-title":"In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis","volume":"6","author":"Warn","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0112","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/AAC.01536-06","article-title":"Serum differentially alters the antifungal properties of echinocandin drugs","volume":"6","author":"Paderu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0113","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/AAC.00478-08","article-title":"In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0114","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/dkn156","article-title":"Micafungin activity against Candida albicans with diverse azole resistance phenotypes","volume":"2","author":"Richards","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000341370","article-title":"Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model","volume":"3\u20134","author":"Takemoto","year":"2012","journal-title":"Pharmacology"},{"key":"2024103013040556000_jphp12780-cit-0116","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"2","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0117","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1128\/AAC.00697-10","article-title":"In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated candidiasis","volume":"10","author":"Kuchar\u00edkov\u00e1","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0118","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1128\/AAC.05198-11","article-title":"Paradoxical caspofungin activity in vivo in preclinical\u0375 aspergillosis: the role of innate immune receptors","volume":"56","author":"Moretti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0119","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/jac\/dkr142","article-title":"Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus","volume":"6","author":"Lewis","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0120","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/424465","article-title":"Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity","volume":"8","author":"Wiederhold","year":"2004","journal-title":"J Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0121","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00829-05","article-title":"Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection","volume":"7","author":"Cacciapuoti","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0122","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.44.3.614-618.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis","volume":"3","author":"Ikeda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0123","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.44.3.619-621.2000","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis","volume":"3","author":"Matsumoto","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0124","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jac\/dkg185","article-title":"Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B","volume":"51","author":"Warn","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0125","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"4","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0126","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/AAC.47.4.1452-1455.2003","article-title":"Efficacy of micafungin alone or in combination against systemic murine aspergillosis","volume":"4","author":"Luque","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0127","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/ja.2013.57","article-title":"Synergistic antifungal activity of KB425796-C in combination with micafungin against Aspergillus fumigatus and its efficacy in murine infection models","volume":"8","author":"Kai","year":"2013","journal-title":"J Antibiot"},{"key":"2024103013040556000_jphp12780-cit-0128","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01282-10","article-title":"In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus","volume":"3","author":"Calvo","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0129","first-page":"796","article-title":"In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus","volume":"2","author":"Seyedmousavi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0130","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.44.9.2259-2262.2000","article-title":"Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice","volume":"9","author":"Ito","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0131","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1128\/AAC.01681-10","article-title":"Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum","volume":"55","author":"Hage","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0132","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.40.8.1811","article-title":"Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo","volume":"8","author":"Bartlett","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0133","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/AAC.00095-07","article-title":"Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences","volume":"51","author":"Chamilos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0134","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1586\/14787210.2013.841543","article-title":"The Eagle-like effect of echinocandins: what's in a name?","volume":"11","author":"Vanstraelen","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024103013040556000_jphp12780-cit-0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/fmb.12.31","article-title":"The postantifungal and paradoxical effects of echinocandins against Candida spp","volume":"5","author":"Moriyama","year":"2012","journal-title":"Future Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0136","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/AAC.00999-10","article-title":"Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum","volume":"6","author":"Shields","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0137","volume-title":"Candida dubliniensis, a species with an extremely high frequency of paradoxical effect with caspofungin, abstr. M1756","author":"Stevens","year":"2006"},{"key":"2024103013040556000_jphp12780-cit-0138","first-page":"881","article-title":"Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species","volume":"3","author":"Antachopoulos","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0139","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1128\/AAC.00563-06","article-title":"Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for \u03b2-1,6-glucan synthesis inhibition by caspofungin","volume":"50","author":"Stevens","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0140","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/AAC.49.12.5146-5148.2005","article-title":"Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways","volume":"49","author":"Wiederhold","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0141","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1128\/AAC.00854-09","article-title":"Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin","volume":"4","author":"Fortwendel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0142","volume-title":"Candida albicans signalling pathways and the regulation of cell wall biosynthesis under stress","author":"De Almeida Nogueira","year":"2013"},{"key":"2024103013040556000_jphp12780-cit-0143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/13693780802428542","article-title":"Paradoxical echinocandin activity: a limited in vitro phenomenon?","volume":"1","author":"Wiederhold","year":"2009","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0144","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1439-0507.2006.01327.x","article-title":"Voriconazole and multidrug resistance in Candida albicans","volume":"2","author":"Wakiec","year":"2007","journal-title":"Mycoses"},{"key":"2024103013040556000_jphp12780-cit-0145","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1128\/AAC.01504-13","article-title":"Multidrug-resistant transporter Mdr1p-mediated uptake of a novel antifungal compound","volume":"12","author":"Sun","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0146","first-page":"11","article-title":"Emerging threats in antifungal-resistant fungal pathogens","volume":"3","author":"Sanglard","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"2024103013040556000_jphp12780-cit-0147","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1128\/AAC.50.4.1148-1155.2006","article-title":"Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility","volume":"4","author":"Niimi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0148","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/AAC.01653-05","article-title":"Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1","volume":"50","author":"Balashov","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0149","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00473-08","article-title":"Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection","volume":"52","author":"Thompson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0150","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than MIC Is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0151","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.1128\/AAC.01973-15","article-title":"Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection","volume":"12","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0152","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1128\/AAC.00836-10","article-title":"FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance","volume":"54","author":"Zimbeck","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0153","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance","volume":"8","author":"Pham","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0154","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/AAC.00998-09","article-title":"Novel FKS mutations associated with echinocandin resistance in Candida species","volume":"54","author":"Garcia-Effron","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/JCM.43.1.214-222.2005","article-title":"Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole","volume":"1","author":"Balashov","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0156","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/JCM.03593-13","article-title":"Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC","volume":"52","author":"Saraya","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2024103013040556000_jphp12780-cit-0157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"3","author":"Perlin","year":"2007","journal-title":"Drug Resist Updat"},{"key":"2024103013040556000_jphp12780-cit-0158","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/jac\/dkq073","article-title":"Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity","volume":"65","author":"Niimi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0159","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1128\/AAC.00123-14","article-title":"Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment","volume":"7","author":"Lackner","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.fgb.2009.09.003","article-title":"Fungal echinocandin resistance","volume":"47","author":"Walker","year":"2010","journal-title":"Fungal Genet Biol"},{"key":"2024103013040556000_jphp12780-cit-0161","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.3109\/13693786.2010.508469","article-title":"Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection","volume":"49","author":"Howard","year":"2010","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0162","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0163","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1128\/AAC.01144-13","article-title":"Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure","volume":"9","author":"Lewis","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0164","first-page":"158","article-title":"Development of echinocandin resistance in Candida krusei isolates following exposure to micafungin and caspofungin in a BM transplant unit","volume":"1","author":"Tavernier","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2024103013040556000_jphp12780-cit-0165","first-page":"243","article-title":"Epidemiology of echinocandin resistance in Candida","volume":"4","author":"Grossman","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"2024103013040556000_jphp12780-cit-0166","doi-asserted-by":"crossref","first-page":"e1002718","DOI":"10.1371\/journal.ppat.1002718","article-title":"Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata","volume":"5","author":"Singh-Babak","year":"2012","journal-title":"PLoS Pathog"},{"key":"2024103013040556000_jphp12780-cit-0167","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/2047-783X-16-4-153","article-title":"Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease \u2013 review of the literature","volume":"16","author":"Mayr","year":"2011","journal-title":"Eur J Med Res"},{"key":"2024103013040556000_jphp12780-cit-0168","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"9","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0169","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"4","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"2024103013040556000_jphp12780-cit-0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"2","author":"Arathoon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0171","first-page":"2020","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis"},{"key":"2024103013040556000_jphp12780-cit-0172","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"11","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0173","volume-title":"Overview of safety experience with caspofungin (CAS) in clinical trials","author":"Taylor"},{"key":"2024103013040556000_jphp12780-cit-0174","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1080\/13693780600860961","article-title":"Clinical efficacy of caspofungin in the treatment of invasive aspergillosis","volume":"1","author":"Aoun","year":"2006","journal-title":"Med Mycol"},{"key":"2024103013040556000_jphp12780-cit-0175","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","article-title":"A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"12","author":"Betts","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0176","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1128\/AAC.00425-10","article-title":"Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients","volume":"54","author":"Groll","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0177","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1128\/AAC.00911-09","article-title":"Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database","volume":"5","author":"Colombo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0178","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-10-182","article-title":"Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry","volume":"1","author":"Maertens","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0179","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-17-7","article-title":"Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry","volume":"17","author":"Egerer","year":"2012","journal-title":"Eur J Med Res"},{"key":"2024103013040556000_jphp12780-cit-0180","first-page":"387","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"3","author":"Kohno","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0181","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/dkl009","article-title":"Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey","volume":"57","author":"Groll","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0182","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.jp.7211637","article-title":"Caspofungin for the treatment of azole resistant candidemia in a premature infant","volume":"2","author":"Smith","year":"2007","journal-title":"J Perinatol"},{"key":"2024103013040556000_jphp12780-cit-0183","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.jp.7211380","article-title":"Experience with caspofungin in the treatment of persistent fungemia in neonates","volume":"12","author":"Natarajan","year":"2005","journal-title":"J Perinatol"},{"key":"2024103013040556000_jphp12780-cit-0184","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-12-151","article-title":"Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0185","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/AAC.00905-10","article-title":"Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients","volume":"5","author":"Li","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0186","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"11","author":"Walsh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0187","doi-asserted-by":"crossref","first-page":"e2016042","DOI":"10.4084\/mjhid.2016.042","article-title":"Outcome of Candida parapsilosis complex infections treated with caspofungin in children","volume":"8","author":"Devrim","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0188","first-page":"143","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"1","author":"Mattiuzzi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0189","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540410020406","article-title":"A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan","volume":"5","author":"Kohno","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0190","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia","volume":"10","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0191","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials","volume":"6","author":"Arrieta","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2024103013040556000_jphp12780-cit-0192","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"10","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024103013040556000_jphp12780-cit-0193","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s10156-012-0391-x","article-title":"The clinical efficacy and safety of micafungin\u2013itraconazole combination therapy in patients with pulmonary aspergilloma","volume":"5","author":"Fujita","year":"2012","journal-title":"J Infect Chemother"},{"key":"2024103013040556000_jphp12780-cit-0194","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.01057-13","article-title":"Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization","volume":"11","author":"Andes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0195","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.bbmt.2010.05.002","article-title":"Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"10","author":"Mehta","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024103013040556000_jphp12780-cit-0196","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2014.136","article-title":"Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT","volume":"9","author":"Park","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2024103013040556000_jphp12780-cit-0197","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2004.02083.x","article-title":"Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent","volume":"4","author":"Pettengell","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103013040556000_jphp12780-cit-0198","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"6","author":"De Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0199","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis","volume":"7","author":"De Wet","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103013040556000_jphp12780-cit-0200","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"10","author":"Van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0201","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2011.557062","article-title":"Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases","volume":"2","author":"Cornely","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"2024103013040556000_jphp12780-cit-0202","first-page":"58","article-title":"Safety of micafungin in prospective and retrospective clinical trials","volume":"55","author":"Ullmann","year":"2016","journal-title":"Mycoses"},{"key":"2024103013040556000_jphp12780-cit-0203","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"6","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024103013040556000_jphp12780-cit-0204","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"6","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0205","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"24","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2024103013040556000_jphp12780-cit-0206","doi-asserted-by":"crossref","DOI":"10.1186\/cc8304","volume-title":"Anidulafungin compared with fluconazole therapy in critically ill patients","author":"Kett","year":"2010"},{"key":"2024103013040556000_jphp12780-cit-0207","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270005281234","article-title":"Safety and pharmacokinetics of coadministered voriconazole and anidulafungin","volume":"12","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2024103013040556000_jphp12780-cit-0208","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/ajt.12963","article-title":"Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients","volume":"12","author":"Winston","year":"2014","journal-title":"Am J Transplant"},{"key":"2024103013040556000_jphp12780-cit-0209","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","article-title":"Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients","volume":"7","author":"Ruhnke","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024103013040556000_jphp12780-cit-0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"2","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0211","first-page":"310","article-title":"Breakthrough fungemia due to candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin \u2013 report of 5 cases","volume":"5","author":"Krcmery","year":"2013","journal-title":"J Chemother"},{"key":"2024103013040556000_jphp12780-cit-0212","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"9390","author":"Denning","year":"2003","journal-title":"Lancet (London, England)"},{"key":"2024103013040556000_jphp12780-cit-0213","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/AAC.00060-12","article-title":"Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise","volume":"6","author":"Neoh","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0214","volume-title":"Cancidas \u2013 caspofungin acetate injection (Drug Approval Package)","year":"2001"},{"key":"2024103013040556000_jphp12780-cit-0215","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"2","author":"Jim\u00e9nez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0216","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"1","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2024103013040556000_jphp12780-cit-0217","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1128\/AAC.48.4.1272-1280.2004","article-title":"Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys","volume":"48","author":"Sandhu","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0218","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0091270005279580","article-title":"Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction","volume":"10","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2024103013040556000_jphp12780-cit-0219","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/AAC.45.12.3322-3327.2001","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits","volume":"12","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0220","first-page":"100","article-title":"Antifungal therapy in the intensive care unit","volume-title":"Infectious Diseases in Critical Care","author":"Paiva","year":"2010"},{"key":"2024103013040556000_jphp12780-cit-0221","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013040556000_jphp12780-cit-0222","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis \u2013 review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur J Med Res"},{"key":"2024103013040556000_jphp12780-cit-0223","first-page":"527","article-title":"Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and\/or invasive candidiasis in nonneutropenic adult patients","volume":"7","author":"Grau","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"2024103013040556000_jphp12780-cit-0224","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/2047-783X-16-4-180","article-title":"Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs \u2013 review of the literature","volume":"16","author":"Wilke","year":"2016","journal-title":"Eur J Med Res"},{"key":"2024103013040556000_jphp12780-cit-0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1600-0609.2007.00850.x","article-title":"A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK","volume":"6","author":"Bruynesteyn","year":"2007","journal-title":"Eur J Haematol"},{"key":"2024103013040556000_jphp12780-cit-0226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14737167.2016.1202766","article-title":"Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses","volume":"4","author":"Mistro","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2024103013040556000_jphp12780-cit-0227","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1185\/03007990802124889","article-title":"Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany","volume":"6","author":"Cornely","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2024103013040556000_jphp12780-cit-0228","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/cc7924","article-title":"Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation","volume":"3","author":"Zilberberg","year":"2009","journal-title":"Crit Care (London, England)"},{"key":"2024103013040556000_jphp12780-cit-0229","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/jac\/dkr186","article-title":"Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis","volume":"8","author":"Neoh","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2024103013040556000_jphp12780-cit-0230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12879-015-1143-1","article-title":"Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis","volume":"1","author":"Auzinger","year":"2015","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/12\/1635\/60231525\/jphp12780.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/12\/1635\/60231525\/jphp12780.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:35:01Z","timestamp":1730313301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/69\/12\/1635\/6127777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":230,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,1]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12780","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12]]},"published":{"date-parts":[[2017,12,1]]}}}